Related references
Note: Only part of the references are listed.Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia
Nicholas J. Donato et al.
BIOCHEMICAL PHARMACOLOGY (2010)
AP24163 Inhibits the Gatekeeper Mutant of BCR-ABL and Suppresses In vitro Resistance
Mohammad Azam et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2010)
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Martin Schwickart et al.
NATURE (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
Ubiquitin C-Terminal Electrophiles Are Activity-Based Probes for Identification and Mechanistic Study of Ubiquitin Conjugating Machinery
Kerry Routenberg Love et al.
ACS CHEMICAL BIOLOGY (2009)
The emerging complexity of protein ubiquitination
David Komander
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells
Ling-Yuan Kong et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53
Saurabh Dayal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
Cristian Bellodi et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Linkage-Specific Avidity Defines the Lysine 63-Linked Polyubiquitin-Binding Preference of Rap80
Joshua J. Sims et al.
MOLECULAR CELL (2009)
Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy
Hyun-Gyung Goh et al.
LEUKEMIA & LYMPHOMA (2009)
Targeting proteins for degradation
Erin K. Schrader et al.
NATURE CHEMICAL BIOLOGY (2009)
Regulation of hematopoiesis by the K63-specific ubiquitin-conjugating enzyme Ubc13
Xuefeng Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Charting the molecular network of the drug target Bcr-Abl
Marc Brehme et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Translation of the Philadelphia chromosome into therapy for CML
Brian J. Druker
BLOOD (2008)
Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
Neil P. Shah et al.
CANCER CELL (2008)
Role of the aggresorne pathway in cancer: Targeting histone deacetylase 6-dependent protein degradation
Agustin Rodriguez-Gonzalez et al.
CANCER RESEARCH (2008)
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation
Srdan Verstovsek et al.
CLINICAL CANCER RESEARCH (2008)
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
Ji Wu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
WP1066 disrupts janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells
Alessandra Ferrajoli et al.
CANCER RESEARCH (2007)
Flying under the radar:: the new wave of BCR-ABL inhibitors
Alfonso Quintas-Cardama et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Heat shock protein 90 - A potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors
Cong Peng et al.
CELL CYCLE (2007)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells
Cong Peng et al.
BLOOD (2007)
Therapeutic targets in chronic myeloid leukaemia
Nicholas B. Heaney et al.
HEMATOLOGICAL ONCOLOGY (2007)
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells
Geoffrey A. Bartholomeusz et al.
BLOOD (2007)
Heat shock protein 90: the cancer chaperone
Len Neckers
JOURNAL OF BIOSCIENCES (2007)
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN 107) therapy failure
Alfonso Quintas-Cardama et al.
BLOOD (2007)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML):: evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides
KJ Aichberger et al.
BLOOD (2005)
Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells
JT Opferman et al.
SCIENCE (2005)
Δ12-prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition
ZM Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl
I Gaston et al.
EXPERIMENTAL HEMATOLOGY (2004)
Protein degradation and protection against misfolded or damaged proteins
AL Goldberg
NATURE (2003)
Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development
JA Wertheim et al.
BLOOD (2003)
Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein
JP Taylor et al.
HUMAN MOLECULAR GENETICS (2003)
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
M Azam et al.
CELL (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death
JE Mullally et al.
MOLECULAR PHARMACOLOGY (2002)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
CL Sawyers et al.
BLOOD (2002)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14
A Borodovsky et al.
EMBO JOURNAL (2001)
Aggresomes, inclusion bodies and protein aggregation
RR Kopito
TRENDS IN CELL BIOLOGY (2000)
Share Paper
